Prototype #37-C is a new wrinkle treatment that is out performing other skin products on the market today. It is the strongest anti-wrinkle serum that is legally sold. The key to the treatment is the 99% peptide concentration and peptides are considered the vital ingredients in the process of anti aging. Those who use this treatment have seen great results within 10 days of the first use. Many see dramatic reduction in wrinkles around the eyes, swollenness under the eyes and dark circles.
Most anti-wrinkle products only contain 2-5% of peptides due to the cost. The formulation of this treatment includes 99% concentration from six different peptides, each that have been patented and proven. The confidence in this product is backed up by a 100% money back guarantee with no questions asked at the time of return.
The many benefits of Prototype #37- C include:
- Being the only product with 99% Peptide concentration
- Ingredients that are safe and will no damage the surrounding skin
- Money back guarantee within 30 days with no questions asked
- Is a leader among other products by 257%
- Strongest anti-wrinkle product on the market
Prototype #37-C Ingredients
Prototype #37-C uses the highest concentration of Peptides including acetyl octapeptide-3, syncoll, acetyl- hexapapeptide-8, matrixyl 3000, eveservyl and pentapeptide- 13. Being the best treatment available today, it is the only one to use 99% concentration of peptide and the other 1% is oil free moisturizer and hyaluronic acid.
Where you can buty Prototype #37-C
Prototype #37-C can be purchased online at many different website. The buying of the product is risk free and comes with a money back guarantee.
The Final Work on Prototype #37-C
Peptides have become very popular in recent anti-aging skin care and Prototype #37-C is able to provide a product with the highest concentration of them. Peptides will reduce the effects of aging on your face, renew the skin as well as produce collagen and elastin. Prototype #37-C is one of a kind and a new revolution on the market today.